NCT05905926
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Enrolling by Invitation
PHASE3Ages 6–18InterventionalHealth servicesArdelyx
~150 participants
Updated 2026-06-04 on ClinicalTrials.gov
What's tested:Tenapanor
At a glance
Recruiting sites
0 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety Measure Assessment (Adverse Event)
Measured over 40 weeks
+1 more outcome measured
Conditions
Where it's being run
27 sites across 14 statesTexas6
Florida5
North Carolina3
New York2
Pennsylvania2
Alabama1
California1
Illinois1
Study leadership
- Jocelyn Tabora · STUDY_DIRECTOR · Ardelyx
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Safety Measure Assessment (Adverse Event)40 weeks
Incidence of AEs, SAEs and drug related adverse events
- Safety Measure Assessment (ECG)40 weeks
Descriptive summaries of ECG parameters (heart rate, PR-interval, QRS-duration, QT-interval, QTc-interval, and RR-interval)